MXPA06001815A - Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson. - Google Patents

Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MXPA06001815A
MXPA06001815A MXPA06001815A MXPA06001815A MXPA06001815A MX PA06001815 A MXPA06001815 A MX PA06001815A MX PA06001815 A MXPA06001815 A MX PA06001815A MX PA06001815 A MXPA06001815 A MX PA06001815A MX PA06001815 A MXPA06001815 A MX PA06001815A
Authority
MX
Mexico
Prior art keywords
disease
active ingredient
transdermal application
containing active
treating parkinson
Prior art date
Application number
MXPA06001815A
Other languages
English (en)
Inventor
Frank Theobald
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34201721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA06001815(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of MXPA06001815A publication Critical patent/MXPA06001815A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Los preparados farmaceuticos transdermicos para el tratamiento de la enfermedad de Parkinson contienen una combinacion de al menos dos principios activos seleccionados de los siguientes grupos de principios activos: agonistas de dopamina y L-dopa, inhibidores de monoamina oxidasa, anticolinergicos, antagonistas del receptor NMDA, simpatomimeticos; al menos dos de dichos principios activos deberan ser miembros de grupos de principios activos diferentes.
MXPA06001815A 2003-08-20 2004-08-14 Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson. MXPA06001815A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10338174A DE10338174A1 (de) 2003-08-20 2003-08-20 Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
PCT/EP2004/009136 WO2005018619A1 (de) 2003-08-20 2004-08-14 Transdermale arzneimittelzubereitungen mit wirkstoffkombinationen zur behandlung der parkinson-krankheit

Publications (1)

Publication Number Publication Date
MXPA06001815A true MXPA06001815A (es) 2006-05-31

Family

ID=34201721

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001815A MXPA06001815A (es) 2003-08-20 2004-08-14 Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.

Country Status (21)

Country Link
US (1) US8980308B2 (es)
EP (1) EP1656122B2 (es)
JP (2) JP2007502795A (es)
KR (1) KR20060065692A (es)
CN (1) CN1832732A (es)
AT (1) ATE446744T1 (es)
AU (1) AU2004266063B2 (es)
BR (1) BRPI0412054A (es)
CA (1) CA2535063C (es)
DE (2) DE10338174A1 (es)
DK (1) DK1656122T4 (es)
ES (1) ES2335771T5 (es)
IL (1) IL173712A (es)
MX (1) MXPA06001815A (es)
NZ (1) NZ545593A (es)
PL (1) PL1656122T5 (es)
PT (1) PT1656122E (es)
RU (1) RU2397757C2 (es)
SI (1) SI1656122T2 (es)
WO (1) WO2005018619A1 (es)
ZA (1) ZA200509779B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8168793B2 (en) 2005-07-26 2012-05-01 Portela & Ca., S.A. Nitrocatechol derivatives as COMT inhibitors
CN101032474B (zh) * 2006-03-06 2011-02-16 重庆医药工业研究院有限责任公司 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
PT2481410T (pt) 2007-01-31 2016-10-18 BIAL-PORTELA & Cª S A Derivados de nitrocatecóis como inibidores da comt administrados num regime posológico específico
ES2521494T3 (es) * 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
EP2150239A1 (en) * 2007-04-24 2010-02-10 Boehringer Ingelheim International GmbH Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
BRPI0913913A2 (pt) * 2008-07-29 2015-10-13 Bial Portela & Ca Sa regime de dosagem para nitrocatecóis
KR20120027197A (ko) 2009-04-01 2012-03-21 바이알 - 포르텔라 앤드 씨에이 에스에이 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
DE102010024105A1 (de) * 2010-06-17 2011-12-22 Grünenthal GmbH Transdermale Verabreichung von Memantin
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHODS FOR TREATING SYMPTOMS IN PATIENTS WITH PARKINSON'S DISEASE
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
CA3088684C (en) 2011-12-13 2021-10-26 Bial - Portela & C.A., S.A. Compound 5-[3-(2,5-dichloro-4,6-dimethyl-1-oxy-pyridin-3-yl)-[1,2,4]oxadiazol-5-yl]-3-nitrobenzene-1,2-diol in microparticulate form and its use in the treatment of parkinson's disease
US20130197023A1 (en) * 2012-01-27 2013-08-01 California Institute Of Technology Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors
JP6050896B2 (ja) 2012-11-02 2016-12-21 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダン経皮組成物
WO2014210544A2 (en) 2013-06-27 2014-12-31 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
CN103622997A (zh) * 2013-11-22 2014-03-12 内蒙古医科大学 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物
EP2946775A1 (de) 2014-05-20 2015-11-25 LTS LOHMANN Therapie-Systeme AG Lavendelöl enthaltendes transdermales therapeutisches System
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
CN104510725B (zh) * 2015-01-22 2021-04-27 中国药科大学 一种普拉克索周效透皮贴剂及其制备方法
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
WO2016145373A1 (en) 2015-03-12 2016-09-15 Chrono Therapeutics Inc. Craving input and support system
CA3003460A1 (en) * 2016-10-07 2018-04-12 Transwell Biotech Co., Ltd. Pramipexole transdermal delivery system and uses thereof
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019232077A1 (en) 2018-05-29 2019-12-05 Chrono Therapeutics Inc. Drug delivery methods and systems
TW202103699A (zh) 2019-04-17 2021-02-01 英商康派斯百事威公司 賽洛西賓（ｐｓｉｌｏｃｙｂｉｎ）於憂鬱及其他各種失調症之治療

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
JPH0611698B2 (ja) 1984-12-19 1994-02-16 大正製薬株式会社 貼付剤
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
ATE55245T1 (de) * 1986-04-16 1990-08-15 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
DE3710966A1 (de) 1986-04-16 1987-12-03 Degussa Synergistische kombination von amantadin und selegilin
US4877618A (en) * 1988-03-18 1989-10-31 Reed Jr Fred D Transdermal drug delivery device
GB8807504D0 (en) 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
US4963568A (en) * 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
BR9306816A (pt) * 1992-07-28 1998-12-08 Procter & Gamble Composição farmaceutica para uso tópico contendo um polímero catiônico reticulado e um eter alcoxilado
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
DE4332094C2 (de) 1993-09-22 1995-09-07 Lohmann Therapie Syst Lts Lösemittelfrei herstellbares Wirkstoffpflaster und Verfahren zu seiner Herstellung
US5744476A (en) * 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
GB9511366D0 (en) 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
DE19626621A1 (de) 1996-07-02 1998-01-08 Hexal Ag Pflaster zur transdermalen Anwendung von Pergolid
US5877173A (en) * 1996-08-28 1999-03-02 Washington University Preventing neuronal degeneration in Alzheimer's disease
JPH11209271A (ja) 1998-01-23 1999-08-03 Nitto Denko Corp 経皮吸収製剤
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
FR2788982B1 (fr) 1999-02-02 2002-08-02 Synthelabo Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique
EP1150661B1 (en) 1999-02-05 2003-10-22 Cipla Ltd. Topical sprays comprising a film forming composition
AU5325000A (en) 1999-06-05 2000-12-28 David Houze Solubility enhancement of drugs in transdermal drug delivery systems and methodsof use
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
FR2798065B1 (fr) 1999-09-02 2003-09-05 Assist Publ Hopitaux De Paris Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
JP2002097137A (ja) 2000-07-19 2002-04-02 Junichi Sudo パーキンソン病の予防および／または治療剤
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
DE10066158B4 (de) 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
DE10064453A1 (de) 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2381630A1 (en) 2001-04-23 2002-10-23 Leonard Theodore Meltzer Method for preventing dyskinesias
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
EP1256339B1 (en) 2001-05-08 2003-10-15 Schwarz Pharma Ag Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit

Also Published As

Publication number Publication date
IL173712A0 (en) 2006-07-05
EP1656122B2 (de) 2012-11-28
PT1656122E (pt) 2010-02-02
JP2007502795A (ja) 2007-02-15
WO2005018619A1 (de) 2005-03-03
SI1656122T1 (sl) 2010-02-26
US20070026054A1 (en) 2007-02-01
PL1656122T5 (pl) 2013-04-30
NZ545593A (en) 2009-09-25
ES2335771T5 (es) 2013-03-26
ES2335771T3 (es) 2010-04-05
CA2535063A1 (en) 2005-03-03
EP1656122B1 (de) 2009-10-28
US8980308B2 (en) 2015-03-17
JP2012092127A (ja) 2012-05-17
ZA200509779B (en) 2006-09-27
DE10338174A1 (de) 2005-03-24
CN1832732A (zh) 2006-09-13
DK1656122T3 (da) 2010-03-08
ATE446744T1 (de) 2009-11-15
RU2397757C2 (ru) 2010-08-27
DE502004010303D1 (de) 2009-12-10
CA2535063C (en) 2014-06-17
AU2004266063B2 (en) 2010-04-08
SI1656122T2 (sl) 2013-03-29
BRPI0412054A (pt) 2006-08-15
JP5827114B2 (ja) 2015-12-02
KR20060065692A (ko) 2006-06-14
EP1656122A1 (de) 2006-05-17
PL1656122T3 (pl) 2010-03-31
AU2004266063A1 (en) 2005-03-03
IL173712A (en) 2010-11-30
RU2005141214A (ru) 2006-07-27
DK1656122T4 (da) 2013-03-11

Similar Documents

Publication Publication Date Title
MXPA06001815A (es) Preparado farmaceutico transdermico que contiene combinaciones de principios activos para el tratamiento de la enfermedad de parkinson.
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
WO2005107726A3 (en) Method for the treatment of back pain
HUP0303197A2 (hu) Alfa-2-adrenerg agonista komponenseket tartalmazó készítmények
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
DE69803360D1 (de) Anwendungsformen zur behandlung der männlichen erektilen dysfunktion
MY143795A (en) Tetrahydropyridoindole derivatives
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
MXPA03000548A (es) Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica.
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
WO2004096118A3 (en) Composition for improving cognition and memory
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog
HK1111924A1 (en) Depigmenting or brightening cosmetic composition comprising at least one oxazolin as an active ingredient
AR033807A1 (es) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
FR2809725B1 (fr) Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant
EP1260221A3 (en) Combination treatment for depression and anxiety
EA200970021A1 (ru) Комбинированные препараты, содержащие slv308 и l-dopa
WO2020168337A4 (en) Compositions and methods for treatment of depression and other disorders
RU2010113924A (ru) Производные 1-аминоалкилциклогексана для лечения кохлеарного тиннитуса

Legal Events

Date Code Title Description
FG Grant or registration